First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Background: The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Patien...

Full description

Bibliographic Details
Main Authors: Wu, Y.L., Zhou, C., Liam, Chong Kin, Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., Huang, C., Qin, S., Zhu, Y., Pan, H., Liang, H., Li, E., Jiang, G., How, S.H., Fernando, M.C.L., Zhang, Y., Xia, F., Zuo, Y.
Format: Article
Published: Elsevier 2015
Subjects:
R Medicine

Similar Items